Breaking News, Collaborations & Alliances

iTolerance, Northway Biotech Partner on Manufacture of Streptavidin-FasL Fusion Protein

Supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102.

iTolerance, Inc., an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression, and Northway Biotech, an end-to-end biologics CDMO, entered into a partnership agreement for the manufacture of iTolerance’s Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the iTOL-100 platform technology. The SA-FasL fusion protein has shown great potential in preclinical studies, establishin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters